Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Decline in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 180,700 shares, a drop of 22.5% from the October 31st total of 233,300 shares. Based on an average daily trading volume, of 78,900 shares, the short-interest ratio is presently 2.3 days. Currently, 0.9% of the company’s shares are sold short.

Aileron Therapeutics Price Performance

Shares of ALRN stock traded up $0.12 on Friday, reaching $2.86. 14,804 shares of the stock were exchanged, compared to its average volume of 73,709. Aileron Therapeutics has a one year low of $1.61 and a one year high of $7.42. The stock has a market cap of $61.98 million, a PE ratio of -0.88 and a beta of 2.35. The stock has a 50 day moving average price of $3.46 and a 200 day moving average price of $3.07.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. KG&L Capital Management LLC acquired a new stake in shares of Aileron Therapeutics during the 3rd quarter worth approximately $46,000. Warberg Asset Management LLC bought a new position in Aileron Therapeutics in the second quarter valued at approximately $86,000. Sigma Planning Corp grew its holdings in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after acquiring an additional 86,185 shares during the period. Geode Capital Management LLC raised its position in shares of Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after acquiring an additional 59,370 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its position in shares of Aileron Therapeutics by 82.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after acquiring an additional 209,367 shares during the last quarter. 90.89% of the stock is currently owned by institutional investors and hedge funds.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).